Drug intelligence / Profile preview

EME-13

Development stage: Preclinical
Lead developer: Epsilon Molecular Engineering
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EME-13 is a preclinical-stage VHH (single-domain antibody or nanobody) candidate being developed by Epsilon Molecular Engineering for the treatment of allergies. Discovered using the company's proprietary cDNA display technology, EME-13 is designed to target key mediators of allergic reactions. As a VHH antibody, it offers advantages such as high stability, solubility, and ease of engineering compared to conventional antibodies, making it a promising therapeutic candidate for allergic diseases.

Beyond the preview

Go deeper on EME-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EME-13.

Explore the full profile